1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > Vertebral Technologies, Inc. - Product Pipeline Analysis, 2016 Update

Summary

Vertebral Technologies, Inc. (VTI) is a medical device company that develops implantable spinal devices. The company offers products such as interfuse S implants, interfuse T implants and motion preservation systems. Its interfuse T implant is a modular implant that joins together through a rail and slot technologies and provides optimal disc support by achieving an ALIF sized footprint through a minimally invasive transformational approach. The company offers its spinal devices based on proprietary intra-operative assembly technologies. It sells its products through a network of distributors in the US. VTI is headquartered in Minnetonka, Minnesota, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Vertebral Technologies, Inc.
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Table Of Contents

Vertebral Technologies, Inc. - Product Pipeline Analysis, 2016 Update
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Vertebral Technologies, Inc. Company Snapshot 5
Vertebral Technologies, Inc. Company Overview 5
Key Information 5
Vertebral Technologies, Inc. Pipeline Products and Clinical Trials Overview 6
Vertebral Technologies, Inc. - Major Products and Services 8
Vertebral Technologies, Inc. Pipeline Products by Development Stage 9
Vertebral Technologies, Inc. Clinical Trials by Trial Status 11
Vertebral Technologies, Inc. Pipeline Products Overview 13
InterCushion Disc Nucleus Replacement System 13
InterCushion Disc Nucleus Replacement System Product Overview 13
InterCushion Disc Nucleus Replacement System Clinical Trial 14
InterFuse DA Intervertebral Body Fusion Device 15
InterFuse DA Intervertebral Body Fusion Device Product Overview 15
InterFuse Intervertebral Body Fusion Device 16
InterFuse Intervertebral Body Fusion Device Product Overview 16
InterFuse L - Intervertebral Body Fusion Device 17
InterFuse L - Intervertebral Body Fusion Device Product Overview 17
InterFuse S Intervertebral Body Fusion Device 18
InterFuse S Intervertebral Body Fusion Device Product Overview 18
InterFuse S Intervertebral Body Fusion Device Clinical Trial 19
InterFuse T - Intervertebral Body Fusion Device 20
InterFuse T - Intervertebral Body Fusion Device Product Overview 20
InterFuse T - Intervertebral Body Fusion Device Clinical Trial 21
Vertebral Technologies, Inc. - Key Competitors 22
Vertebral Technologies, Inc. - Key Employees 23
Vertebral Technologies, Inc. - Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Vertebral Technologies, Inc., Recent Developments 25
May 01, 2012: Vertebral Technologies Implants Over 2,000 InterFuse Interbody Fusion Devices In US 25
Jan 06, 2010: VIT Implants Its InterFuse Interbody Fusion Device Using Intraoperative Assembly Technology In 500th Patient 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
Vertebral Technologies, Inc., Key Facts 5
Vertebral Technologies, Inc. Pipeline Products and Clinical Trials Overview 6
Vertebral Technologies, Inc. Pipeline Products by Equipment Type 6
Vertebral Technologies, Inc. Pipeline Products by Indication 7
Vertebral Technologies, Inc. Clinical Trials by Trial Status 7
Vertebral Technologies, Inc., Major Products and Services 8
Vertebral Technologies, Inc. Number of Pipeline Products by Development Stage 9
Vertebral Technologies, Inc. Pipeline Products Summary by Development Stage 10
Vertebral Technologies, Inc. Clinical Trials by Trial Status 11
Vertebral Technologies, Inc. Clinical Trials Summary 12
InterCushion Disc Nucleus Replacement System - Product Status 13
InterCushion Disc Nucleus Replacement System - Product Description 13
InterCushion Disc Nucleus Replacement System - A Pilot Clinical Study to Assess the Safety and Effectiveness of the InterCushion Disc Nucleus Prosthesis in Patients Receiving Discectomy 14
InterFuse DA Intervertebral Body Fusion Device - Product Status 15
InterFuse DA Intervertebral Body Fusion Device - Product Description 15
InterFuse Intervertebral Body Fusion Device - Product Status 16
InterFuse Intervertebral Body Fusion Device - Product Description 16
InterFuse L - Intervertebral Body Fusion Device - Product Status 17
InterFuse L - Intervertebral Body Fusion Device - Product Description 17
InterFuse S Intervertebral Body Fusion Device - Product Status 18
InterFuse S Intervertebral Body Fusion Device - Product Description 18
InterFuse S Intervertebral Body Fusion Device - A Multi-center Prospective Study of VTI InterFuse S and InterFuse T for the Treatment of Scoliosis, Spondylolisthesis and Degenerative Disc Disease 19
InterFuse T - Intervertebral Body Fusion Device - Product Status 20
InterFuse T - Intervertebral Body Fusion Device - Product Description 20
InterFuse T - Intervertebral Body Fusion Device - A Multi-center Prospective Study of VTI InterFuse S and InterFuse T for the Treatment of Scoliosis, Spondylolisthesis and Degenerative Disc Disease 21
InterFuse T - Intervertebral Body Fusion Device - A Prospective Study of the InterFuse T 21
Vertebral Technologies, Inc., Key Employees 23

List of Figures
Vertebral Technologies, Inc. Pipeline Products by Equipment Type 7
Vertebral Technologies, Inc. Pipeline Products by Development Stage 9
Vertebral Technologies, Inc. Clinical Trials by Trial Status 11

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Glutamyl Aminopeptidase ...

Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Pipeline Review, H2 2016

Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Leukotriene A 4 Hydrolase (LTA 4 Hydrolase ...

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H2 2016

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.